Skip to main content

Table 3 Muscle Areas Injected With OnabotulinumtoxinA Stratified by Administration Session

From: An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study

Muscle Areas Injected, n (%)a

Admin 1

N = 633

Admin 2

N = 573

Admin 3

N = 485

Admin 4

N = 420

Admin 5

N = 371

Admin 6

N = 329

Admin 7

N = 275

Admin 8

N = 200

Right side

 Frontalis

630 (99.5)

570 (99.5)

481 (99.2)

417 (99.3)

369 (99.5)

326 (99.1)

274 (99.6)

199 (99.5)

 Corrugator

623 (98.4)

560 (97.7)

472 (97.3)

404 (96.2)

361 (97.3)

321 (97.6)

268 (97.5)

191 (95.5)

 Occipitalis

625 (98.7)

565 (98.6)

475 (97.9)

410 (97.6)

361 (97.3)

323 (98.2)

268 (97.5)

193 (96.5)

 Temporalis

631 (99.7)

570 (99.5)

482 (99.4)

416 (99.0)

368 (99.2)

327 (99.4)

273 (99.3)

198 (99.0)

 Trapezius

619 (97.8)

562 (98.1)

477 (98.4)

412 (98.1)

366 (98.7)

324 (98.5)

273 (99.3)

192 (96.0)

 Cervical

609 (96.2)

546 (95.3)

465 (95.9)

406 (96.7)

357 (96.2)

318 (96.7)

259 (94.2)

184 (92.0)

 Other

67 (10.6)

53 (9.2)

44 (9.1)

42 (10.0)

35 (9.4)

29 (8.8)

29 (10.5)

23 (11.5)

Left side

 Frontalis

628 (99.2)

570 (99.5)

480 (99.0)

418 (99.5)

370 (99.7)

327 (99.4)

274 (99.6)

199 (99.5)

 Corrugator

621 (98.1)

559 (97.6)

471 (97.1)

405 (96.4)

361 (97.3)

320 (97.3)

267 (97.1)

191 (95.5)

 Occipitalis

622 (98.3)

565 (98.6)

474 (97.7)

411 (97.9)

361 (97.3)

323 (98.2)

267 (97.1)

193 (96.5)

 Temporalis

629 (99.4)

570 (99.5)

481 (99.2)

417 (99.3)

369 (99.5)

328 (99.7)

273 (99.3)

196 (98.0)

 Trapezius

618 (97.6)

563 (98.3)

476 (98.1)

412 (98.1)

366 (98.7)

325 (98.8)

273 (99.3)

191 (95.5)

 Cervical

608 (96.1)

546 (95.3)

465 (95.9)

406 (96.7)

357 (96.2)

317 (96.4)

258 (93.8)

184 (92.0)

 Other

66 (10.4)

52 (9.1)

44 (9.1)

40 (9.5)

36 (9.7)

29 (8.8)

29 (10.5)

23 (11.5)

Midline

 Frontalis

0

0

1 (0.2)

0

0

0

0

0

 Procerus

584 (92.3)

534 (93.2)

454 (93.6)

394 (93.8)

352 (94.9)

310 (94.2)

256 (93.1)

182 (91.0)

 Other

0

0

0

0

0

0

0

0

  1. aPercentages are based on the number of patients who received onabotulinumtoxinA at that administration session